Turner, Nicholas <br/><br/>
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.  [electronic resource] 

 -  Cancer research  Mar 2010 
 - 2085-94 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-09-3746  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Hormonal--pharmacology<br/>Breast Neoplasms--drug therapy<br/>Cell Adhesion--genetics<br/>Cell Growth Processes--genetics<br/>Cell Line, Tumor<br/>Drug Resistance, Neoplasm<br/>Estradiol--analogs & derivatives<br/>Female<br/>Fibroblast Growth Factor 2--pharmacology<br/>Fulvestrant<br/>Gene Amplification<br/>Gene Silencing<br/>Humans<br/>MAP Kinase Signaling System<br/>Mitogen-Activated Protein Kinase 1--metabolism<br/>Mitogen-Activated Protein Kinase 3--metabolism<br/>Phosphatidylinositol 3-Kinases--metabolism<br/>Phosphorylation<br/>RNA, Messenger--biosynthesis<br/>Receptor, Fibroblast Growth Factor, Type 1--biosynthesis<br/>Receptors, Estrogen--biosynthesis<br/>Tamoxifen--analogs & derivatives